Tanaka Rie, Murata Hiroshi, Takamoto Mitsuko, Ohtomo Kazuyoshi, Okinaga Kimiko, Yoshida Atsushi, Kawashima Hidetoshi, Nakahara Hisae, Fujino Yujiro, Kaburaki Toshikatsu
Department of Ophthalmology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
Department of Ophthalmology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Br J Ophthalmol. 2016 Jul;100(7):990-994. doi: 10.1136/bjophthalmol-2015-307362. Epub 2015 Nov 9.
To investigate the ability of the Behçet's disease ocular attack score 24 (BOS24) scoring system to predict visual acuity (VA) in patients with ocular Behçet's disease.
This is a retrospective study.
We included 91 eyes of 50 patients with ocular Behçet's disease (33 males, 17 females) who were referred to our hospital between 1986 and 2008 with >5 years follow-up. Total BOS24 scores over a 5-year period, BOS24-5Y, were calculated as the sum of BOS24 scores for each attack over the 5-year study period for each eye. Change in VA was defined as change in best-corrected visual acuity (BCVA) from the first remission to the last remission at the end of the target period. Factors related to change in VA (age, gender, BCVA at the first remission, total number of immunosuppressive medications and total number of ocular attacks during the 5-year period and BOS24-5Y) were evaluated using a linear mixed model.
BCVA (logarithm of the minimal angle resolution) deteriorated from 0.16±0.30 (mean±SD) to 0.21±0.37 over the 5-year study period, but there was no statistical difference. The total number of ocular attacks during the 5-year period and BOS24-5Y scores were 10.0±7.9 and 36.8±40.8, respectively. Linear mixed-model analysis revealed that BOS24-5Y was the most important index for VA deterioration, followed by BCVA at the first remission.
BOS24-5Y was found to be a significant positive prognostic index for VA deterioration in patients with ocular Behçet's disease.
研究白塞病眼部发作评分24(BOS24)系统预测白塞病眼病患者视力(VA)的能力。
这是一项回顾性研究。
我们纳入了1986年至2008年间转诊至我院且随访时间超过5年的50例白塞病眼病患者的91只眼睛(男性33例,女性17例)。计算每只眼睛在5年研究期内每次发作的BOS24评分总和,即5年BOS24评分(BOS24 - 5Y)。视力变化定义为目标期结束时从首次缓解到最后缓解的最佳矫正视力(BCVA)变化。使用线性混合模型评估与视力变化相关的因素(年龄、性别、首次缓解时的BCVA、5年期间免疫抑制药物的总数、眼部发作总数以及BOS24 - 5Y)。
在5年研究期内,最小分辨角对数视力(logMAR)从0.16±0.30(均值±标准差)恶化至0.21±0.37,但无统计学差异。5年期间眼部发作总数和BOS24 - 5Y评分分别为10.0±7.9和36.8±40.8。线性混合模型分析显示,BOS24 - 5Y是视力恶化的最重要指标,其次是首次缓解时的BCVA。
发现BOS24 - 5Y是白塞病眼病患者视力恶化的显著阳性预后指标。